Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: atticus4paws who wrote (50715)	1/31/2019 9:36:38 PM
From: Miljenko Zuanic	Respond to of 52153

<that MDGL/VKTX results crush those of BMY's FGF21 by an order of magnitude> I do not have baseline data fro BMY (Lancet article is not free), but I doubt very much that difference in fat reduction is whole order of magnitude. Anyway, fat reduction is not the only measurement that count in NASH. As I mentioned several time, here and on VKTX/MDGL boards..I placed my bet (after disappointment in VKTX management) on MDGL, PREMATURELY!